Tesofensine: Side Effects & Safety

Tesofensine is a triple monoamine reuptake inhibitor — it blocks reuptake of serotonin, norepinephrine, and dopamine simultaneously. The combined sympathomimetic activation produces robust weight loss but also predictable cardiovascular effects (heart rate, blood pressure) that have slowed regulatory approval in the US and EU. Phase 3 trials have run primarily in Mexico under the Saniona / Medix Tesomet program.^[1]

This regulatory caution exists because of the history of sympathomimetic weight-loss drugs (sibutramine / Meridia withdrawn from US/EU markets 2010 for cardiovascular events; phentermine restricted; rimonabant withdrawn for psychiatric events). Tesofensine's safety story has been judged against that backdrop. The peripheral signals on its own (modest mean HR/BP changes) are not dramatic; the question is whether population-level cardiovascular outcomes over years of use mirror or differ from sibutramine. That question is not yet answered.

Tesofensine is not FDA-approved. It is not on the July 2026 FDA Pharmacy Compounding Advisory Committee 503A bulks list agenda. The Tesomet protocol (tesofensine + metoprolol) is the most-advanced regulatory path, primarily through Mexican approval.

Pooled from Astrup et al. Phase 2 (Lancet 2008) and Tesomet Phase 3 trials.^[1][2]

Effect	0.5 mg/day	1.0 mg/day	Notes
Dry mouth	~50%	~60%	Most common; noradrenergic + anticholinergic-like effect
Insomnia / disrupted sleep	~30%	~40%	Worst with afternoon/evening dosing; morning dose mandatory
Constipation	~20%	~25%	Serotonergic / anticholinergic-like
Heart rate increase	+7–8 bpm	+9–10 bpm	Sustained throughout dosing; monitor weekly initially
Blood pressure increase	+1–3 mmHg SBP	+3–6 mmHg SBP	Modest; mean values mask individual outliers
Anxiety / irritability	~10–15%	~20%	Dopamine/norepinephrine elevation
Mood changes (broader)	~10%	~15%	Includes dysphoria; monitor for psychiatric effects
Headache	Occasional	More common	Usually transient first 1–2 weeks
Nausea	Mild, occasional	More common	Usually mild
Discontinuation due to adverse events	~5%	~10%	Mostly cardiovascular or psychiatric

The cardiovascular signal is the central safety question. Norepinephrine reuptake inhibition raises peripheral sympathetic tone, producing modest dose-dependent increases in resting heart rate and blood pressure.

Magnitude

• 0.5 mg/day: mean +7–8 bpm HR, +1–3 mmHg SBP at steady state.
• 1.0 mg/day: mean +9–10 bpm HR, +3–6 mmHg SBP at steady state.

Why this matters more than the numbers suggest

Mean values mask outliers. Some patients respond with substantially larger increases. Sibutramine's withdrawal in 2010 was driven by the SCOUT trial finding a 16% increase in major cardiovascular events over 6 years in patients with pre-existing cardiovascular disease — despite mean BP/HR changes that, on paper, looked tolerable. The regulatory caution around tesofensine reflects this lesson.

Tesomet (tesofensine + metoprolol)

The most-advanced clinical program combines tesofensine with the beta-blocker metoprolol to offset the heart-rate increase. Phase 3 data suggests metoprolol blunts the HR signal without diminishing weight-loss efficacy.^[2]

Monitoring

• Resting HR and BP at baseline.
• Weekly during the first month.
• Monthly thereafter.
• Sustained HR > baseline + 10 bpm or SBP > baseline + 10 mmHg → dose reduction or discontinuation.

Tesofensine inhibits serotonin reuptake. Combined with other serotonergic drugs, the resulting excess serotonin can produce serotonin syndrome — a potentially fatal condition characterized by:

• Confusion, agitation, restlessness
• Hyperthermia (often > 38°C)
• Sweating, shivering
• Hypertension, tachycardia
• Myoclonus, hyperreflexia, tremor
• Severe cases: seizures, rhabdomyolysis, multi-organ failure, death

Trigger drug categories:

• MAOIs (phenelzine, tranylcypromine, selegiline, isocarboxazid, linezolid, methylene blue): absolute contraindication. Lethal combination.
• SSRIs/SNRIs: high risk. Avoid combining.
• Triptans (sumatriptan, etc.): moderate risk.
• Tramadol, meperidine, fentanyl: moderate risk.
• St. John's Wort, 5-HTP, tryptophan supplements: moderate risk.
• Lithium: moderate risk.
• MDMA / illicit serotonergic drugs: high risk.

If serotonin syndrome is suspected: stop tesofensine immediately and seek emergency care.

• Uncontrolled hypertension or systolic BP > 140 / diastolic > 90 at baseline.
• Known cardiovascular disease (coronary artery disease, heart failure, arrhythmia, history of MI or stroke).
• Concurrent MAOIs (or within 14 days of MAOI discontinuation): absolute contraindication.
• Concurrent SSRIs / SNRIs without psychiatric supervision.
• History of substance abuse (theoretical abuse potential via dopamine pathway).
• Severe anxiety disorders or psychosis (may worsen).
• Hyperthyroidism (additive sympathomimetic effects).
• Pheochromocytoma (risk of hypertensive crisis).
• Pregnancy and breastfeeding: not recommended; insufficient safety data.
• Severe renal or hepatic impairment.
• Pediatric use: not studied.
• Known hypersensitivity.

Additional drug interactions

• Sympathomimetics (pseudoephedrine, ephedrine, phenylephrine): additive cardiovascular effects.
• Stimulants (amphetamines, methylphenidate, modafinil): additive sympathetic and dopaminergic activation.
• Dopamine agonists (levodopa, cabergoline, ropinirole): theoretical additive dopaminergic activity.
• Bupropion, atomoxetine: additive monoaminergic effects.
• Caffeine: additive cardiovascular effects; minimize intake.
• Anesthetics, surgical drugs: inform anesthesiologist of tesofensine use; consider holding for 2–3 days before surgery if cardiovascular status allows.

• Persistent dry mouth: hydrate, sugar-free gum, dental check-ups (chronic dry mouth increases caries risk).
• Sleep disruption: confirm dose is morning (before 9 AM); reduce dose; minimize evening caffeine.
• HR or BP elevation beyond threshold: reduce dose or discontinue. Consider Tesomet combination (with prescriber supervision).
• Anxiety, irritability, mood changes: reduce dose; if persistent, discontinue. Monitor for emerging psychiatric symptoms.
• Signs of serotonin syndrome (confusion + sweating + hyperthermia + hyperreflexia): emergency care immediately.
• Chest pain, palpitations, syncope: emergency evaluation for cardiac events.
• Allergic reaction: discontinue immediately and seek emergency care.

See the tesofensine complete guide, dosage protocols, benefits and research, and the peptides for weight loss overview.